AllianceBernstein
INBX

AllianceBernstein’s Inhibrx, Inc. Common Stock INBX Stock Holding History

AllianceBernstein’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-35,860
Closed -$1.25M – 3360
2024
Q1 		$1.25M Sell
35,860
-35,629
-50% -$1.3M ﹤0.01% 2141
2023
Q4 		$2.72M Sell
71,489
-20,040
-22% -$429K ﹤0.01% 1778
2023
Q3 		$1.68M Buy
91,529
+46,092
+101% +$964K ﹤0.01% 1976
2023
Q2 		$1.18M Buy
45,437
+10,237
+29% +$239K ﹤0.01% 2198
2023
Q1 		$664K Hold
35,200
– – ﹤0.01% 2424
2022
Q4 		$867K Hold
35,200
– – ﹤0.01% 2356
2022
Q3 		$632K Sell
35,200
-161,202
-82% -$2.91M ﹤0.01% 2531
2022
Q2 		$2.23M Buy
196,402
+93,686
+91% +$1.38M ﹤0.01% 1892
2022
Q1 		$2.29M Sell
102,716
-8,313
-7% -$212K ﹤0.01% 2006
2021
Q4 		$4.85M Buy
111,029
+11,427
+11% +$457K ﹤0.01% 1638
2021
Q3 		$3.32M Buy
99,602
+75,626
+315% +$2.3M ﹤0.01% 1846
2021
Q2 		$660K Buy
+23,976
New +$499K ﹤0.01% 2701

Other funds holding INBX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

AllianceBernstein's INBX Position: Q2 2024 in Review

AllianceBernstein sold out of Inhibrx, Inc. Common Stock (INBX) in Q2 2024, closing a stake of 35,860 shares — an estimated $1.25M sold.

AllianceBernstein first reported a position in INBX in Q2 2021 and held it in 12 quarters. The position peaked at $4.85M in Q4 2021. 2 funds tracked by Wall St. Rank hold INBX as of Q2 2024.

  • AllianceBernstein reported no remaining Inhibrx, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • AllianceBernstein sold 35,860 Inhibrx, Inc. Common Stock shares in Q2 2024, an estimated $1.25M.
  • AllianceBernstein first reported a position in Inhibrx, Inc. Common Stock in Q2 2021 and held it in 12 quarters.
  • AllianceBernstein's Inhibrx, Inc. Common Stock position peaked at $4.85M in Q4 2021.
  • 2 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q2 2024.

Based on AllianceBernstein's 13F filing for Q2 2024, filed 14 Aug 2024.